Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Factors Affecting Benefit/Harm Of Intensive Glucose Control In Type 2 Diabetes Reported
Factors affecting whether intensive glucose control is likely to reduce or increase the risk of cardiovascular events, including death, based on evidence in the VA Diabetes Trial, were reported in a symposium here today at the American Diabetes Association"s 69th Scientific Sessions.
generic viagra online
Number Of Abortion Procedures Continues To Decline In Minnesota And Wisconsin
The following summarizes news coverage of state abortion statistics in Minnesota and Wisconsin.~ Minnesota: The number of abortions performed in Minnesota decreased for the second consecutive year in 2008, according to an annual report from the state Department of Health, the Minneapolis Star Tribune reports. Except for a one-time increase in 2006, the number of abortions in Minnesota has trended downward since a peak in 1980, when 19,028 procedures were performed. The new report found that 12,948 abortions were performed in the state in 2008, a decrease of 895 from 2007. Women ages 20 to 24 accounted for about one-third of the procedures, the most among any age group. The number of procedures among teenagers continued a decline that began in the 1990s but had leveled off slightly earlier this decade, the report found. The report also found that less than one-third of women reported using contraception and about one in seven was married at the time of conception (Von Sternberg, Minneapolis Star Tribune, 7/1).~ Wisconsin: Wisconsin abortion providers performed 8,229 procedures in 2008, the lowest number since the state began collecting statistics in 1974, according to an annual report by the state Department of Health Services, the AP/Milwaukee Journal-Sentinel reports. The number of abortions has declined annually since 2003, when 10,557 procedures were performed. State law requires abortion providers to provide DHS with the data. According to the report, slightly more than half of abortions took place in the first eight weeks of pregnancy. Women who had never been married accounted for about three-fourths of all procedures. The report found that 12% of abortions occurred among women ages 35 and older; 34% were among women ages 20 to 24; 11% were among women ages 18 and 19; and 6% were among girls ages 15 to 17. The number of abortions among minors decreased from 551 in 2007 to 500 in 2008, with parents providing consent in 452 of those cases (Richmond, AP/Milwaukee Journal-Sentinel, 6/30).
News of the day
Nucletron Releases Comprehensive Film-and Volume-Based Planning System For Wide Variety Of Brachy Solutions
Nucletron, a knowledge-based leader in radiation oncology,
Public Health

Access Pharmaceuticals Announces Publication Of Thiarabine Combination Data

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced that new Thiarabine preclinical efficacy data will shortly be published demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either agent alone. In one colorectal cancer model, 66% of mice were cured of their tumors. The publication which will appear in the journal "Cancer Chemotherapy and Pharmacology," was based on work conducted by Access" collaborators at the Southern Research Institute. The paper is entitled "Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine" (thiarabine). "Thiarabine is a next generation nucleoside analogue, licensed by Access from Southern Research Institute," stated Jeffrey Davis, President & CEO. "Thiarabine has been in two Phase 1/2 solid tumor trials and was shown to have significant anti-tumor activity. Access is working with leukemia and lymphoma specialists at M.D. Anderson Cancer Center in Houston to initiate additional Phase 2 clinical trials in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and other indications. Additionally, we are actively seeking co-development partners, and believe that thiarabine could have applications in certain solid tumors as well," he continued. In the study, thiarabine, clofarabine, and their combinations were tested in five tumor models. "In all cases, thiarabine demonstrated superior tumor growth inhibition than clofarabine when the agents were used alone," commented David P Nowotnik, Ph.D., Access Pharmaceuticals" Senior Vice President, Research and Development. "But, in the combination of these two agents, efficacy was dramatically superior to the use of either agent alone. Tumor regression and cures were observed in several models including colorectal cancer and leukemia. The combination of agents proved to be effective even when used at low doses, indicating a potential for effective treatment with a reduced side-effect profile." Prior clinical studies have shown that the effectiveness of cytarabine, or Ara-C, (a close structural analog of thiarabine which is widely used in treating leukemia patients) can be improved by combining it with clofarabine in the treatment of leukemia patients. The Southern Research paper showed that thiarabine/clofarabine combinations have significantly superior efficacy to cytarabine/clofarabine combinations in the xenograft models. Thiarabine has previously been shown to have much better solid tumor efficacy than cytarabine in preclinical models. About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access" products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access" plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access" need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access" Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission. Access Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009